Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial

Published:2022-06 Issue: Volume:Volume 15 Page:737-747
ISSN:1178-6965
Container-title:Journal of Asthma and Allergy
language:en
Short-container-title:JAA

Author:

Davidescu Lavinia^ORCID,Ursol Grygoriy,Korzh Oleksii^ORCID,Deshmukh Vikrant,Kuryk Lesia,Nortje Monja-Marie,Godlevska Olga,Devouassoux Gilles,Khodosh Eduard,Israel Elliot,Moussy Alain,Mansfield Colin D^ORCID,Hermine Olivier,Chanez Pascal

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy

Reference25 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

2. Global Initiative for Asthma. Global strategy for asthma management and prevention; 2020. Available from www.ginasthma.org. Accessed May 23, 2022.

3. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena

4. Mast cells in asthma: Here I am, stuck in the middle with you

5. Treatment options in type-2 low asthma

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Pathways and Potential Therapeutic Targets of Refractory Asthma;Biology;2024-08-01

2. Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials;Neurological Sciences;2024-04-17

3. The pharmacological management of asthma in adults: 2023 update;Expert Opinion on Pharmacotherapy;2024-03-03

4. Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development;Expert Opinion on Investigational Drugs;2023-11-02

5. Poorly controlled asthma – Easy wins and future prospects for addressing fungal allergy;Allergology International;2023-10